AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $38,000.00 income · posted Jan 15, 2026

Lobbying activity 1

Health Issues

- ultrarare disease - newborn screening - pediatric priority review voucher

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.